BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 30928903)

  • 1. Development and validation of the Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI): a novel instrument to quantify organ damage in systemic sclerosis.
    Ferdowsi N; Huq M; Stevens W; Hudson M; Wang M; Tay T; Burchell JL; Mancuso S; Rabusa C; Sundararajan V; Prior D; Proudman SM; Baron M; Nikpour M; ;
    Ann Rheum Dis; 2019 Jun; 78(6):807-816. PubMed ID: 30928903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and Initial Validation of the Novel Scleroderma Clinical Trials Consortium Activity Index.
    Ross L; Hansen D; Proudman S; Khanna D; Herrick AL; Stevens W; ; ; Baron M; Nikpour M;
    Arthritis Rheumatol; 2024 Jun; ():. PubMed ID: 38937146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anemia Is an Indicator for Worse Organ Damage Trajectories in Patients with Systemic Sclerosis: A Retrospective Study.
    Li Z; Xu D; Jiang X; Li T; Su Y; Mu R
    J Clin Med; 2022 Aug; 11(17):. PubMed ID: 36078943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term organ damage accrual and late mortality in systemic sclerosis.
    Lazzaroni MG; Moschetti L; Breda M; Franceschini F; Airò P
    Clin Exp Rheumatol; 2023 Oct; ():. PubMed ID: 37933549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reliability and validity of the Korean version of the University of California-Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract instrument in patients with systemic sclerosis.
    Lee TH; Lee JS; Park S; Lee KA; Kim HS
    Korean J Intern Med; 2021 Nov; 36(6):1504-1514. PubMed ID: 33561335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reliability and validity of the Italian version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument in patients with systemic sclerosis.
    Gualtierotti R; Ingegnoli F; Two R; Meroni PL; Khanna D; Adorni G; Becciolini A; Ciavarella T; Marfia G; Murgo A; Scalone L; Ughi N; Zeni S;
    Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S55-60. PubMed ID: 26339890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a provisional core set of response measures for clinical trials of systemic sclerosis.
    Khanna D; Lovell DJ; Giannini E; Clements PJ; Merkel PA; Seibold JR; Matucci-Cerinic M; Denton CP; Mayes MD; Steen VD; Varga J; Furst DE;
    Ann Rheum Dis; 2008 May; 67(5):703-9. PubMed ID: 17893248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Damage Trajectories in Systemic Sclerosis Using Group-Based Trajectory Modeling.
    Barbacki A; Baron M; Wang M; Zhang Y; Stevens W; Sahhar J; Proudman S; Nikpour M; Man A;
    Arthritis Care Res (Hoboken); 2023 Mar; 75(3):640-647. PubMed ID: 35226416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correction:
    Ann Rheum Dis; 2019 Aug; 78(8):e88. PubMed ID: 31296652
    [No Abstract]   [Full Text] [Related]  

  • 10. Prevalence and correlates of sleep disturbance in systemic sclerosis--results from the UCLA scleroderma quality of life study.
    Frech T; Hays RD; Maranian P; Clements PJ; Furst DE; Khanna D
    Rheumatology (Oxford); 2011 Jul; 50(7):1280-7. PubMed ID: 21324979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The validity and reliability study of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract (UCLA SCTC GIT) 2.0 questionnaire for the Turkish society.
    Taş YM; Derviş Hakim G; Keskinoğlu P; Kenar G; Yarkan H; Zengin B; Can G; Önen F; Akkoç N; Birlik M; Akarsu M
    Turk J Gastroenterol; 2019 Mar; 30(3):234-241. PubMed ID: 30541712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reliability and validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument.
    Khanna D; Hays RD; Maranian P; Seibold JR; Impens A; Mayes MD; Clements PJ; Getzug T; Fathi N; Bechtel A; Furst DE
    Arthritis Rheum; 2009 Sep; 61(9):1257-63. PubMed ID: 19714600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of the UCLA Scleroderma Clinica Trial Gastrointestinal Tract Instrument version 2.0 for systemic sclerosis.
    Baron M; Hudson M; Steele R; Lo E;
    J Rheumatol; 2011 Sep; 38(9):1925-30. PubMed ID: 21724704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome measurements in scleroderma: results from a delphi exercise.
    Gazi H; Pope JE; Clements P; Medsger TA; Martin RW; Merkel PA; Kahaleh B; Wollheim FA; Baron M; Csuka ME; Emery P; Belch JF; Hayat S; Lally EV; Korn JH; Czirjak L; Herrick A; Voskuyl AE; Bruehlmann P; Inanc M; Furst DE; Black C; Ellman MH; Moreland LW; Rothfield NF; Hsu V; Mayes M; McKown KM; Krieg T; Siebold JR
    J Rheumatol; 2007 Mar; 34(3):501-9. PubMed ID: 17299843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-resolution manometry compared with the University of California, Los Angeles Scleroderma Clinical Trials Consortium GIT 2.0 in Systemic Sclerosis.
    Abozaid HSM; Imam HMK; Abdelaziz MM; El-Hammady DH; Fathi NA; Furst DE
    Semin Arthritis Rheum; 2017 Dec; 47(3):403-408. PubMed ID: 28624173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Associations between the Composite Response Index in Diffuse Cutaneous Systemic Sclerosis (CRISS), survival and other disease measures.
    Zheng B; Wang M; Stevens W; Proudman S; Nikpour M; Baron M; ;
    Semin Arthritis Rheum; 2022 Apr; 53():151973. PubMed ID: 35149318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient-reported outcome instruments for assessing Raynaud's phenomenon in systemic sclerosis: A SCTC Vascular Working Group Report.
    Pauling JD; Frech TM; Hughes M; Gordon JK; Domsic RT; Anderson ME; Ingegnoli F; McHugh NJ; Johnson SR; Hudson M; Boin F; Ong VH; Matucci-Cerinic M; Altorok N; Scolnik M; Nikpour M; Shah A; Pope JE; Khanna D; Herrick AL
    J Scleroderma Relat Disord; 2018 Oct; 3(3):249-252. PubMed ID: 30705970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exercise.
    Fransen J; Johnson SR; van den Hoogen F; Baron M; Allanore Y; Carreira PE; Czirják L; Denton CP; Distler O; Furst DE; Gabrielli A; Herrick A; Inanc M; Kahaleh B; Kowal-Bielecka O; Medsger TA; Mueller-Ladner U; Riemekasten G; Sierakowski S; Valentini G; Veale D; Vonk MC; Walker U; Chung L; Clements PJ; Collier DH; Csuka ME; Jimenez S; Merkel PA; Seibold JR; Silver R; Steen V; Tyndall A; Matucci-Cerinic M; Pope JE; Khanna D
    Arthritis Care Res (Hoboken); 2012 Mar; 64(3):351-7. PubMed ID: 22052558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic review of systemic sclerosis-specific instruments for the EULAR Outcome Measures Library: An evolutional database model of validated patient-reported outcomes.
    Ingegnoli F; Carmona L; Castrejon I
    Semin Arthritis Rheum; 2017 Apr; 46(5):609-614. PubMed ID: 27839740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Translation, cross-cultural adaptation, and validation of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument (SCTC GIT) 2.0 into Dutch.
    Meijs J; Pors D; Vliet Vlieland TP; Huizinga TW; Schouffoer AA
    Clin Exp Rheumatol; 2014; 32(6 Suppl 86):S-41-8. PubMed ID: 24984228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.